NATICK, Mass., Dec. 11, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced that the underwriters for its initial public offering of common stock have fully exercised their option to purchase an additional 1,020,000 shares of common stock at the public offering price of $16.00 per share, less underwriting discounts. Proceeds to Karyopharm from the exercise of the option were approximately $15.2 million, after deducting underwriting discounts. The closing of the option exercise occurred December 10, 2013.
Help employers find you! Check out all the jobs and post your resume.
